These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 24713153)

  • 21. Impact of right-to-left shunt and transcatheter closure on the clinical features of migraine.
    He Q; Zhang Y; Wang F; Li C; Guo R; Li X; Luan B; Zhao H; Meng L; Chen H; Meng L
    Int J Neurosci; 2020 Mar; 130(3):270-275. PubMed ID: 31549584
    [No Abstract]   [Full Text] [Related]  

  • 22. Transcatheter interatrial shunt closure as a cure for migraine: can it be justified by paradoxical embolism-risk-driven criteria?
    Rigatelli G; Cardaioli P; Giordan M; Dell'Avvocata F; Braggion G; Chianaglia M; Roncon L
    Am J Med Sci; 2009 Mar; 337(3):179-81. PubMed ID: 19301452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
    Aral M; Mullen M
    Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of recurrent stroke after percutaneous closure of patent foramen ovale despite residual right-to-left cardiac shunt assessed by transcranial Doppler.
    van de Wyngaert F; Kefer J; Hermans C; Ovaert C; Pasquet A; Beguin C; Sindic C; Sluysmans T
    Arch Cardiovasc Dis; 2008; 101(7-8):435-41. PubMed ID: 18848685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Residual shunt after patent foramen ovale closure: preliminary results from Italian patent foramen ovale survey.
    Caputi L; Butera G; Anzola GP; Carminati M; Carriero MR; Chessa M; Onorato E; Rigatelli G; Sangiorgi G; Santoro G; Spadoni I; Ussia GP; Vigna C; Zanchetta M; Parati E;
    J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e219-26. PubMed ID: 23352683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual shunt after percutaneous closure of patent foramen ovale with AMPLATZER occluder devices - influence of anatomic features: a transcranial Doppler and intracardiac echocardiography study.
    Marchese N; Pacilli MA; Inchingolo V; Fanelli R; Loperfido F; Vigna C
    EuroIntervention; 2013 Jul; 9(3):382-8. PubMed ID: 23872652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Embolic implications of combined risk factors in patients with patent foramen ovale (the CARPE criteria): consideration for primary prevention closure?
    Rigatelli G; Dell'Avvocata F; Giordan M; Braggion G; Aggio S; Chinaglia M; Roncon L; Cardaioli P; Chen JP
    J Interv Cardiol; 2009 Aug; 22(4):398-403. PubMed ID: 19515082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of patent foramen ovale closure with no-device left behind: first-in-man percutaneous suture closure.
    Ruiz CE; Kipshidze N; Chiam PT; Gogorishvili I
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):921-6. PubMed ID: 18412251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Residual Right-to-Left-Shunt Following Transcatheter Patent Foramen Ovale Closure: The Role of Antithrombotic Treatment.
    Katsianos E; Oikonomou E; Kalogeras K; Manousaki A; Kalantzis C; Pantelidis P; Vavuranakis MA; Aggeli K; Siasos G; Tsioufis C; Vavuranakis M
    Curr Pharm Des; 2022; 28(40):3305-3312. PubMed ID: 36306457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Migraine Intervention With STARFlex Technology (MIST) trial: a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache.
    Dowson A; Mullen MJ; Peatfield R; Muir K; Khan AA; Wells C; Lipscombe SL; Rees T; De Giovanni JV; Morrison WL; Hildick-Smith D; Elrington G; Hillis WS; Malik IS; Rickards A
    Circulation; 2008 Mar; 117(11):1397-404. PubMed ID: 18316488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An audit of persistent foramen ovale closure in 105 divers.
    Pearman A; Bugeja L; Nelson M; Szantho GV; Turner M
    Diving Hyperb Med; 2015 Jun; 45(2):94-7. PubMed ID: 26165531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Medium-term results of transcatheter closure of patent foramen ovale (PFO) with Amplatzer PFO and Cribriform occluders.
    Białkowski J; Wawrzyńczyk M; Karwot B; Fiszer R; Knop M; Szkutnik M
    Kardiol Pol; 2012; 70(11):1142-6. PubMed ID: 23180522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The value of right heart contrast echocardiography combined with migraine rating scale in evaluating the efficacy of patent foramen ovale closure.
    Niu Y; Pan J; Fan S; Wang L; Tang X
    BMC Cardiovasc Disord; 2023 Aug; 23(1):390. PubMed ID: 37558988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of patent foramen ovale closure on visual aura without headache or typical aura with migraine headache.
    Khessali H; Mojadidi MK; Gevorgyan R; Levinson R; Tobis J
    JACC Cardiovasc Interv; 2012 Jun; 5(6):682-7. PubMed ID: 22721665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transcatheter closure of patent foramen ovale in patients with paradoxical embolism. Procedural and follow-up results after implantation of the Starflex occluder device with conjunctive intensified anticoagulation regimen.
    Fischer D; Fuchs M; Schaefer A; Schieffer B; Jategaonkar S; Hornig B; Drexler H; Meyer GP
    J Interv Cardiol; 2008 Apr; 21(2):183-9. PubMed ID: 18312307
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
    Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
    J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Echocardiographic findings in simple and complex patent foramen ovale before and after transcatheter closure.
    Vitarelli A; Mangieri E; Capotosto L; Tanzilli G; D'Angeli I; Toni D; Azzano A; Ricci S; Placanica A; Rinaldi E; Mukred K; Placanica G; Ashurov R
    Eur Heart J Cardiovasc Imaging; 2014 Dec; 15(12):1377-85. PubMed ID: 25139906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is it too early to recommend patent foramen ovale closure for all patients who suffer from migraine? A single-centre study.
    Chessa M; Colombo C; Butera G; Negura D; Piazza L; Varotto L; Bussadori C; Fesslova V; Meola G; Carminati M
    J Cardiovasc Med (Hagerstown); 2009 May; 10(5):401-5. PubMed ID: 19449455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of residual shunts after initial percutaneous patent foramen ovale closure: a single center experience with immediate and long-term follow-up.
    Diaz T; Cubeddu RJ; Rengifo-Moreno PA; Cruz-Gonzalez I; Solis-Martin J; Buonanno FS; Inglessis I; Palacios IF
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):145-50. PubMed ID: 20578100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of patent foramen ovale closure in patients with platypnea-orthodeoxia syndrome.
    Mojadidi MK; Gevorgyan R; Noureddin N; Tobis JM
    Catheter Cardiovasc Interv; 2015 Oct; 86(4):701-7. PubMed ID: 26063336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.